Why weren’t there any big deals announced this week? What does the word “equivalar” mean? And why is information about prognosis so hard to find?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we recap what happened — and what didn’t — this week at the J.P. Morgan Healthcare Conference in San Francisco. Then, we talk about one of the biggest stories of the conference — the launch of a new company called EQRx aiming to develop cheaper medicines — with the health care veteran behind it, Alexis Borisy. Finally, we chat with Stephen Buck, the entrepreneur behind a new website called CancerSurvivalRates.com, which is designed to give cancer patients information about their odds of survival.
For more on what we cover, here are all of the stories we wrote about J.P. Morgan; here’s the news on EQRx; and here’s more on CancerSurvivalRates.com.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
Bezos, Dimon & Buffet.
Healthy, wealthy & wise.
Preventative & curative is better than proprietary & proscriptive.
Conference is typically about sickness benefits.
But no gold pill this year. Telling?
I like health benefits better.
For me, my friends & my family.
Many seem to like sickness benefits.
If health was working in this country (USA), we’d have more of it.
It is not easy for any media outlet to cover everything going during JPM week. As a former reporter I know you are going to be attracted to the “big story news.” But it would be interesting to take a look at some of the up and company smaller companies which present at the Biotech Showcase where the next big news story may come from.
Comments are closed.